Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis

Infection and Immunity

Volumn 80, Issue 2, 2012, Pages 602-611

  Brudecki, Laura ^a   Ferguson, Donald A ^a   Yin, Deling ^a   Lesage, Gene D ^a   Mccall, Charles E ^b   Gazzar, Mohamed El ^a  

^a East Tennessee State University   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL PERITONITIS; BONE MARROW; CECUM; CELL DIFFERENTIATION; CELL TRACKING; CELL TRANSFER; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INTESTINE SURGERY; MALE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; SEPSIS; SURVIVAL;

ANIMALS; ANTIGENS, CD34; HEMATOPOIETIC STEM CELLS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; NEUTROPHILS; PERITONEUM; PERITONITIS; SEPSIS; STEM CELL TRANSPLANTATION; TIME FACTORS;

EID: 84857165509     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05480-11     Document Type: Article

References (68)

1. Abraham E, et al. 1997. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277: 1531-1538.
2. Adolfsson J, et al. 2001. Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 15:659-669.
3. Adolfsson J, et al. 2005. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 121:295-306.
4. Akashi K, Traver D, Miyamoto T, Weissman IL. 2000. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404:193-197.
5. Angus DC, et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
6. Ayala A, Chaudry IH. 1996. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 6(Suppl 1):S27-S38.
7. Ayala A, Urbanich MA, Herdon CD, Chaudry IH. 1996. Is sepsisinduced apoptosis associated with macrophage dysfunction? J. Trauma 40:568-573.
8. Baker CC, Chaudry IH, Gaines HO, Baue AE. 1983. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335.
9. Baue AE. 1996. MOF/MODS, SIRS: an update. Shock 6(Suppl 1):S1-S5.
10. Beasley D, Schwartz JH, Brenner BM. 1991. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J. Clin. Invest. 87: 602-608.
11. Belikoff B, Hatfield S, Sitkovsky M, Remick DG. 2011. Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice. Shock 35:382-387.
12. Belikoff BG, et al. 2011. A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J. Immunol. 186:2444-2453.
13. Biffl WL, et al. 1996. Interleukin-6 delays neutrophil apoptosis. Arch. Surg. 131:24-29.
14. Bone RC, et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655.
15. Chen CZ, Li L, Lodish HF, Bartel DP. 2004. MicroRNAs modulate hematopoietic lineage differentiation. Science 303:83-86.
16. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. 1992. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80:2012-2020.
17. Cunha BA. 1995. Antibiotic treatment of sepsis. Med. Clin. North Am. 79:551-558.
18. Delano MJ, et al. 2007. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204:1463-1474.
19. Dinarello CA. 1997. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112:321S-329S.
20. Docke WD, et al. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678-681.
21. El Gazzar M, Yoza BK, Hu JY, Cousart SL, McCall CE. 2007. Epigenetic silencing of tumor necrosis factor alpha during endotoxin tolerance. J. Biol. Chem. 282:26857-26864.
22. Ellaban E, Bolgos G, Remick D. 2004. Selective macrophage suppression during sepsis. Cell. Immunol. 231:103-111.
23. Ertel W, et al. 1997. Inhibition of the defense system stimulating interleukin-12 interferon-gamma pathway during critical illness. Blood 89:1612-1620.
24. Ertel W, et al. 1995. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85:1341-1347.
25. Ertel W, et al. 1991. The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann. Surg. 214: 141-148.
26. Fisher CJ, Jr, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836-1843.
27. Fisher CJ, Jr, et al. 1994. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22:12-21.
28. Groeneveld AB, Tacx AN, Bossink AW, van Mierlo GJ, Hack CE. 2003. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin. Immunol. 106:106-115.
29. Haslett C. 1992. Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. Clin. Sci. (Lond.) 83:639-648.
30. Hotchkiss RS, et al. 2000. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1:496-501.
31. Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138-150.
32. Hotchkiss RS, Nicholson DW. 2006. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6:813-822.
33. Huang X, et al. 2009. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl. Acad. Sci. U. S. A. 106:6303-6308.
34. Lederer JA, Rodrick ML, Mannick JA. 1999. The effects of injury on the adaptive immune response. Shock 11:153-159.
35. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M. 2004. Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J. Immunol. 173:21-24.
36. Madonna GS, Vogel SN. 1985. Early endotoxin tolerance is associated with alterations in bone marrow-derived macrophage precursor pools. J. Immunol. 135:3763-3771.
37. Mazuski JE, et al. 2002. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg. Infect. (Larchmt.) 3:161-173.
38. McCall CE, Yoza B, Liu T, El Gazzar M. 2010. Gene-specific epigenetic regulation in serious infections with systemic inflammation. J. Innate Immun. 2:395-405.
39. Meakins JL, et al. 1977. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann. Surg. 186:241-250.
40. Munoz C, et al. 1991. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88:1747-1754.
41. Nagy RD, et al. 2005. Stem cell transplantation as a therapeutic approach to organ failure. J. Surg. Res. 129:152-160.
42. Nemeth K, et al. 2009. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15:42-49.
43. Nemzek JA, Xiao HY, Minard AE, Bolgos GL, Remick DG. 2004. Humane endpoints in shock research. Shock 21:17-25.
44. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. 1990. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552.
45. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. 1988. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. 81:1162-1172.
46. Osuchowski MF, Welch K, Siddiqui J, Remick DG. 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177:1967-1974.
47. Osuchowski MF, Welch K, Yang H, Siddiqui J, Remick DG. 2007. Chronic sepsis mortality characterized by an individualized inflammatory response. J. Immunol. 179:623-630.
48. Randow F, et al. 1995. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J. Exp. Med. 181:1887-1892.
49. Reinhart K, Karzai W. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29:S121-S125.
50. Remick DG. 2007. Pathophysiology of sepsis. Am. J. Pathol. 170:1435-1444.
51. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467.
52. Rice TW, Bernard GR. 2005. Therapeutic intervention and targets for sepsis. Annu. Rev. Med. 56:225-248.
53. Sands KE, et al. 1997. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 278:234-240.
54. Seatter SC, Li MH, Bubrick MP, West MA. 1995. Endotoxin pretreatment of human monocytes alters subsequent endotoxin-triggered release of inflammatory mediators. Shock 3:252-258.
55. Shelley O, Murphy T, Paterson H, Mannick JA, Lederer JA. 2003. Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury. Shock 20:123-129.
56. Szabo G, Romics L Jr, Frendl G. 2002. Liver in sepsis and systemic inflammatory response syndrome. Clin. Liver Dis. 6:1045-1066.
57. Tracey KJ, et al. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664.
58. Tyndall A, Pistoia V. 2009. Mesenchymal stem cells combat sepsis. Nat. Med. 15:18-20.
59. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. 2009. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J. Leukoc. Biol. 86:219-227.
60. Vianna RC, et al. 2004. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 21:115-120.
61. Wang H, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-242.
62. Weil BR, et al. 2010. Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery 148:444-452.
63. Weil BR, et al. 2009. Stem cells in sepsis. Ann. Surg. 250:19-27.
64. Weston SA, Parish CR. 1990. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J. Immunol. Methods 133:87-97.
65. Williams MA, Withington S, Newland AC, Kelsey SM. 1998. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J. Infect. Dis. 178:1421-1433.
66. Wysocka M, Montaner LJ, Karp CL. 2005. Flt3 ligand treatment reverses endotoxin tolerance-related immunoparalysis. J. Immunol. 174:7398-7402.
67. Xiao H, Siddiqui J, Remick DG. 2006. Mechanisms of mortality in early and late sepsis. Infect. Immun. 74:5227-5235.
68. Ziegler-Heitbrock HW, Frankenberger M, Wedel A. 1995. Tolerance to lipopolysaccharide in human blood monocytes. Immunobiology 193: 217-223.